- Home
- HCM vs VCEL Comparison
HCM vs VCEL Comparison
Compare HCM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCM | VCEL |
|---|---|---|
| Founded | 2000 | 1989 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HCM | VCEL |
|---|---|---|
| Price | $14.01 | $39.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $22.01 | ★ $60.57 |
| AVG Volume (30 Days) | 52.5K | ★ 499.1K |
| Earning Date | 07-30-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $14.24 | $21.71 |
| Revenue Next Year | $11.52 | $16.86 |
| P/E Ratio | $5.49 | ★ N/A |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $9.77 | $28.95 |
| 52 Week High | $16.33 | $49.32 |
Technical Indicators
Market Signals| Indicator | HCM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 47.51 |
| Support Level | $13.70 | $37.78 |
| Resistance Level | $14.44 | $41.12 |
| Average True Range (ATR) | 0.30 | 1.29 |
| MACD | -0.09 | 0.17 |
| Stochastic Oscillator | 39.44 | 56.02 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.